Gastrointestinal and cardiovascular risk of nonsteroidal anti-inflammatory drugs

Oman Medical Journal

Volumn 26, Issue 6, 2011, Pages 385-391

  Al Saeed, Abdulwahed ^a  

^a Department of Medicine Dammam Medical Complex Hospital ^*  (Saudi Arabia)

Author keywords

Cyclo oxygenase 1(COX 1); Cyclo oxygenase 2(COX 2); Nonsteroidal anti inflammatory drugs (NSAIDS)

Indexed keywords

EID: 84858174738     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2011.101     Document Type: Review

References (112)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun;340(24):1888-1899.
2. American Gastroenterological Association. Patient Center. http://www.gastro.org/wmspage.cfm?parm1=5815(accessed Jan 23, 2010).
3. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol Suppl 1990 Feb;20:12-19.
4. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed? A review and metaanalysis. J Clin Gastroenterol 1993 Oct;17(3):238-243.
5. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996 Jun;25(2):373-396.
6. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl 1991 Mar;28:6-10.
7. Bollini P, García Rodríguez LA, Pérez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992 Jun;152(6):1289-1295.
8. McMahon AD, Evans JM, White G, Murray FE, McGilchrist MM, McDevitt DG, et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. J Clin Epidemiol 1997 Mar;50(3):351-356.
9. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinalcomplications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991 Nov;115(10):787-796.
10. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 Apr;343(8905):1075-1078.
11. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997 Nov;315(7119):1333-1337.
12. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug;123(4):241-249.
13. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005 Aug;112(5):759-770.
14. O'Malley P. The risks and benefits of non steroidal anti-inflammatory agents for pain: implications for the clinical nurse specialist. Clin Nurse Spec 2002 Sep;16(5):270-273.
15. Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 2005;35(4):347-385.
16. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007 Jul; 5(7):818-828,
17. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborativemeta-analysis. BMJ 1996 Jun;312(7046):1563-1566.
18. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Non steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991 Feb;114(4):257-263.
19. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997 Jan;8(1):18-24.
20. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998 May;51:8-16.
21. Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs; drugcontaining renal and biliary stones; diclofenac and carprofen approved. Arthritis Rheum 1988;31:1450-1451.
22. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000 Jul;95(7):1681-1690.
23. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:235-239.
24. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000 Jan;43(1):4-13.
25. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999 May;339(Pt 3):607-614.
26. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC., et al. Expression and selective inhibition of the constitutive and inducible formsof human cyclo-oxygenase. Biochem J 1995 Jan;305(Pt 2):479-484.
27. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996 Jun;25(2):279-298.
28. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the highrisk patient. Gastroenterology 2001 Feb;120(3):594-606.
29. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983 May;74(5):820-828.
30. Konturek SJ, Kwiecień N, Obtułowicz W, Kopp B, Oleksy J. Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and micro bleeding in normal and aspirin treated man. Gut 1986 Dec;27(12):1450-1456.
31. Tseng CC, Wolfe MM. Nonsteroidal anti-inflammatory drugs. Med Clin North Am 2000 Sep;84(5):1329-1344.
32. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: Arandomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep;284(10):1247-1255.
33. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa anddyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987 Nov;82(11):1153-1158.
34. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and lifethreatening complications of peptic ulceration. Gut 1987 May;28(5):527-532.
35. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditionalnon-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 2004 Jul;20(Suppl 2):48-58.
36. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999;26(Suppl 26):18-24.
37. Hernández-Díaz S, García-Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001 Feb;110(Suppl 3A):20S-27S.
38. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al; Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999 Oct;117(4):776-783.
39. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al; The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000 Feb;43(2):370-377.
40. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999 Nov;282(20):1921-1928.
41. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996 Jul;6(3):489-504.
42. Robert A, Schultz JR, Nezamis JE, Lancaster C. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration. Gastroenterology 1976Mar;70(3):359-370.
43. Carmichael HA, Nelson L, Chandra V, Lyon A, Cochran KM, Russell RI. Proceedings: Inhibition of aspirin and taurocholic acid-induced gastric mucosal bleeding by prostaglandin 15(R)15 methyl-E2 methyl ester. Gut 1975 Oct;16(10):822.
44. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006 Jan;116(1):4-15.
45. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar;352(11):1071-1080.
46. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 Jun;332(7553):1302-1308.
47. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 Oct;296(13):1633-1644.
48. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008 Apr;117(16):2104-2113
49. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008 Apr;117(16):2104-2113.
50. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006 Jun;113(25):2906-2913.
51. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, et al. Increased mortality and cardiovascular morbidity associated with use of non steroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009 Jan;169(2):141-149.
52. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160(6):777-784.
53. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993 Feb;153(4):477-484.
54. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994 Aug;121(4):289-300.
55. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-controlanalysis. BMJ 2005 Dec;331(7528):1310-1316.
56. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528.
57. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286(8):954-959.
58. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
59. Carné X, Cruz N. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Eur J Epidemiol 2005;20(2):127-129.
60. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005 Aug;112(5):759-770.
61. US Food and Drug Administration. FDA issues public health advisory recommending limited use of COX-2 inhibitors. FDA Talk Paper. December 23, 2004. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01336.html.(Accessed Jan 23, 2010).
62. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug;364(9435):675-684.
63. US Food and Drug Administration. FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs. FDA Consumer Magazine. May-June 2005 Issue. Available at: http://www.fda.gove/fdac/features/2005/305_NSAID.html. (Accessed Jan 23, 2010).
64. Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology (Oxford) 2007 Jun;46(6):911-919.
65. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z. Different Mechanisms in Formation and Prevention of Indomethacin-induced Gastric Ulcers. Inflammation. 2010 Jan 19. [Epub ahead of print].
66. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007 Feb;132(2):498-506.
67. Hernández-Díaz S, Rodríguez LA. Association between non steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000; 24;160(14):2093-2099.
68. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 Jun;332(7553):1302-1308.
69. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006 Mar;98(3):266-274.
70. Roth SH, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation. Arch Intern Med 1987 Oct;147(10):1798-1801.
71. Roth SH. Efficacy of antacid therapy for NSAID-induced symptomatic gastropathy. Pract Gastroenterol 1994;18:14-20.
72. Caldwell JR, Roth SH, Wu WC, Semble EL, Castell DO, Heller MD, et al. Sucralfate treatment of nonsteroidal anti-inflammatory druginduced gastrointestinal symptoms and mucosal damage. Am J Med 1987 Sep;83(3B):74-82.
73. Gudjonsson H, Oddsson E, Thjodleifsson B. Protective effect of sucralfate against naproxen induced damage to the human gastroduodenal mucosa (Abstract 12). Scand J Gastroenterol 1990;25(Suppl 76):24.
74. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, et al. Miso prostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial.Ann Intern Med 1991 Aug;115(3):195-200.
75. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988 Oct;297(6655):1017-1021.
76. Robinson MG, Griffin JW Jr, Bowers J, Kogan FJ, Kogut DG, Lanza FL, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis ci 1989 Mar;34(3):424-428.
77. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994 Feb;39(2):362-365.
78. Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 1991;18(Suppl 28):ll-14.
79. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, et al; Misoprostol Study Group. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993Aug;119(4):257-262.
80. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988 Dec;2(8623):1277-1280.
81. Jiranek GC, Kimmey MB, Saunders DR, Willson RA, Shanahan W, Silverstein FE. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology 1989 Feb;96(2 Pt 2)(Suppl):656-661.
82. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.
83. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000 Sep;43(9):1905-1915.
84. Lanza FL; Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998 Nov;93(11):2037-2046.
85. MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001 Oct;135(8 Pt 2):711-721.
86. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al; TARGET Study Group. Comparison of lumiracoxib with naproxenand ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004 Aug;364(9435):665-674.
87. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 Mar;352(11):1081-1091.
88. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused bynonsteroidal anti inflammatory drugs. N Engl J Med 1996 May;334(22):1435-1439.
89. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiin flammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998 Mar;338(11):719-726.
90. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998 Mar;338(11):727-734.
91. Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 2007 Sep;133(3):790-798.
92. Höer A, Gothe H, Schiffhorst G, Sterzel A, Grass U, Häussler B. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclo fenac or other NSAIDs in combination with protonpump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf 2007 Aug;16(8):854-858.
93. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007 Feb;132(2):498-506.
94. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, et al; Investigators of the Asociación Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents,and anticoagulants. Am J Gastroenterol 2007 Mar;102(3):507-515.
95. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. NEngl J Med 2001 Mar;344(13):967-973.
96. Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgrad Med J 2001 Feb;77(904):82-88.
97. García Rodríguez LA, Ruigómez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology 1999May;10(3):228-232.
98. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al; SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006 Mar;119(3):255-266.
99. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002 Dec;347(26):2104-2110.
100. Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004 Oct;127(4):1038-1043.
101. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005 Nov;118(11):1271-1278.
102. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med 2002 Dec;347(26):2162-2164.
103. Cryer B. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID induced ulcers? Gastroenterology 2004 Oct;127(4):1256-1258.
104. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase- 2-specific inhibitors and proton pump inhibitors in patients requiring chronicanti-inflammatory therapy. Aliment Pharmacol Ther 2004 Jan;19(2):197-208.
105. Chan FK. Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006 Oct;3(10):563-573.
106. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006 Apr;101(4):701-710.
107. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995 Mar;141(6):539-545.
108. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 Mar;343(8900):769-772.
109. Lanza LL, Walker AM, Bortnichak EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 1995 Jul;155(13):1371-1377.
110. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995May;30(5):438-444.
111. García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998 Jan;158(1):33-39.
112. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007 May;369(9573):1580-1581.